Impli is a pioneering biotechnology company dedicated to revolutionizing accessibility and efficacy in the world of in vitro fertilization (IVF). Our breakthrough innovation, a biosensing platform, a novel combination of electronics and subdermal biosensors, allows for the continuous monitoring of hormones crucial for egg retrieval, embryo transfer, and pregnancy development. Leveraging NFC technology, the device communicates seamlessly with modern smartphones, providing instant readings of three vital hormone levels. This capability eliminates the need for frequent blood draws, offering a convenient and accurate approach to enhancing IVF outcomes.
Founded in April 2019, Impli was conceived with a mission to improve lives through cutting-edge implantable technology. Our inaugural product, ImpliCaspian, set the standard by enabling users to store and access medical information effortlessly via a smartphone app. Since then, our vision has evolved, focusing on the future of biosensors and the development of innovative products that provide real-time, hassle-free access to personal health data at the touch of a phone.
The promise of our technology heralds a transformative era for IVF, with the potential to make it more accessible, reduce the number of required cycles, and significantly increase successful pregnancy rates. Our advancements have garnered recognition, including a feature in the Octopus Ventures Future of Fertility Report. At Impli, we are committed to shaping a healthier and safer world through the power of biotechnology one IVF journey at a time.
-
Industry
-
Medical Equipment Manufacturing
-
Company size
-
2-10 employees
-
Headquarters
-
London, London
-
Type
-
Privately Held
-
Founded
-
2019
-
Specialties
-
Biotechnology, Implantables, NFC, Data, AI, Machine learning, Software, Medical ID, Hormone, Femtech, Implantable tech, Healthcare, Medtech, ImpliCaspian, fertility, and IVF
